scholarly journals Multicenter cohort study on the survival time of cancer patients dying at home or in a hospital: Does place matter?

Cancer ◽  
2016 ◽  
Vol 122 (9) ◽  
pp. 1453-1460 ◽  
Author(s):  
Jun Hamano ◽  
Takashi Yamaguchi ◽  
Isseki Maeda ◽  
Akihiko Suga ◽  
Takayuki Hisanaga ◽  
...  
Keyword(s):  
Cohort Study ◽  
Survival Time ◽  
Cancer Patients ◽  
Multicenter Cohort Study ◽  
Multicenter Cohort ◽  
Dying At Home ◽  
At Home

Long-Term Central Venous Catheter Infection in HIV-infected and Cancer Patients: A Multicenter Cohort Study

1999 ◽  
Vol 20 (7) ◽  
pp. 494-498 ◽  
Author(s):  
Pascal Astagneau ◽  
Sylvie Maugat ◽  
Tuan Tran-Minh ◽  
Marie-Cécile Douard ◽  
Pascale Longuet ◽  
...  
Keyword(s):  
Cohort Study ◽  
Central Venous Catheter ◽  
Cancer Patients ◽  
Venous Catheter ◽  
Central Venous ◽  
Hiv Patients ◽  
Multicenter Cohort Study ◽  
Multicenter Cohort ◽  
Hiv And Cancer

Objectives:To evaluate and compare the risk of long-term central venous catheter (CVC) infection in human immunodeficiency virus (HIV)-infected and cancer patients.Design:Prospective multicenter cohort study based on active surveillance of long-term CVC manipulations and patient outcome over a 6-month period.Setting:Services of infectious diseases and oncology of 12 university hospitals in Paris, France.Participants:In 1995, all HIV and cancer patients with solid malignancy were included at the time of long-term CVC implantation.Results:Overall, 31.6% of long-term CVC infections were identified in 32% of 201 HIV and 5% of 255 cancer patients. Most were associated with bacteremia, most commonly coagulase-negative staphylococci. The long-term CVC time-related infection risk was greater in HIV than in cancer patients (3.78 vs 0.39 infections per 1,000 long-term CVC days; P<.001). The independent risk factors of long-term CVC infection were as follows: in HIV patients, frequency of long-term CVC handling and neutropenia; in cancer patients, poor Karnofsky performance status; in both HIV and cancer patients, recent history of bacterial infection. The risk of long-term CVC infection was similar for tunneled catheters and venous access ports in each population.Conclusions:Prevention of long-term CVC infection should focus first on better sterile precautions while handling long-term CVC, especially in HIV patients who have frequent and daily use of the long-term CVC.

scholarly journals Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study

PLoS ONE ◽  
2014 ◽  
Vol 9 (12) ◽  
pp. e115060 ◽  
Author(s):  
Pierre Soubeyran ◽  
Carine Bellera ◽  
Jean Goyard ◽  
Damien Heitz ◽  
Hervé Curé ◽  
...  
Keyword(s):  
Cohort Study ◽  
Cancer Patients ◽  
Multicenter Cohort Study ◽  
Multicenter Cohort ◽  
Older Cancer Patients

scholarly journals Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4749
Author(s):  
Marc-Antoine Benderra ◽  
Ainhoa Aparicio ◽  
Judith Leblanc ◽  
Demian Wassermann ◽  
Emmanuelle Kempf ◽  
...  
Keyword(s):  
Cohort Study ◽  
Mortality Rate ◽  
Cancer Patients ◽  
Multicenter Cohort Study ◽  
Related Factors ◽  
Reactive Protein ◽  
Multicenter Cohort ◽  
All Cause Mortality ◽  
Male Sex ◽  
Metabolic Comorbidities

Background: COVID-19 may be more frequent and more severe in cancer patients than in other individuals. Our aims were to assess the rate of COVID-19 in hospitalized cancer patients, to describe their demographic characteristics, clinical features and care trajectories, and to assess the mortality rate. Methods: This multicenter cohort study was based on the Electronic Health Records of the Assistance Publique-Hôpitaux de Paris (AP-HP). Cancer patients with a diagnosis of COVID-19 between 3 March and 19 May 2020 were included. Main outcome was all-cause mortality within 30 days of COVID-19 diagnosis. Results: A total of 29,141 cancer patients were identified and 7791 (27%) were tested for SARS-CoV-2. Of these, 1359 (17%) were COVID-19-positive and 1148 (84%) were hospitalized; 217 (19%) were admitted to an intensive care unit. The mortality rate was 33% (383 deaths). In multivariate analysis, mortality-related factors were male sex (aHR = 1.39 [95% CI: 1.07–1.81]), advanced age (78–86 y: aHR = 2.83 [95% CI: 1.78–4.51] vs. <66 y; 86–103 y: aHR = 2.61 [95% CI: 1.56–4.35] vs. <66 y), more than two comorbidities (aHR = 2.32 [95% CI: 1.41–3.83]) and C-reactive protein >20 ng/mL (aHR = 2.20 [95% CI: 1.70–2.86]). Primary brains tumors (aHR = 2.19 [95% CI: 1.08–4.44]) and lung cancer (aHR = 1.66 [95% CI: 1.02–2.70]) were associated with higher mortality. Risk of dying was lower among patients with metabolic comorbidities (aHR = 0.65 [95% CI: 0.50–0.84]). Conclusions: In a hospital-based setting, cancer patients with COVID-19 had a high mortality rate. This mortality was mainly driven by age, sex, number of comorbidities and presence of inflammation. This is the first cohort of cancer patients in which metabolic comorbidities were associated with a better outcome.

Sign in / Sign up

Export Citation Format

Share Document